Imugene Limited announced the appointment of Ursula McCurry and Dr. Nimali Withana to its senior management team. They are both former Roche/Genentech employees and experts in oncology clinical development, commencing their positions with Imugene on 1 January 2022. Ursula McCurry is appointed as the Senior Vice President of Clinical Operations.

Prior to joining Imugene, Ursula served as the VP of Clinical Operations at Amunix Pharmaceuticals and prior to that was a Clinical Program Director at Genentech, leading multiple programs from entry into the clinic to phase three development, including taselisib and GDC-9545. Dr. Nimali Withana is appointed Senior Director of Clinical Science and has over 18 years of drug development experience spanning both academia and industry. Most recently she was the Lead Country Medical Manager for the Breast Cancer and Cancer Immunotherapy portfolios including bevacizumab, trastuzumab emtansine, ipatasertib and atezolizumab at Hoffman-La Roche New Zealand.

Prior to that, she was the Clinical Scientist Lead across Phase I ­ III global oncology trials at Genentech.